Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

1. Trump proposes up to 25% tariffs on imported pharmaceuticals affecting the industry. 2. AbbVie faces significant risks alongside Merck due to high import volume. 3. Analysts remain uncertain about the overall impact of potential tariffs. 4. Pharmaceutical manufacturers are urging gradual tariff implementation for economic stability. 5. Costs may be passed to patients and providers if tariffs are implemented.